1-10 of 10
Michael Tees
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial)

Free
Matthew Frank, David Qualls, Armin Ghobadi, Jordan Gauthier, Michael Tees, Luke Mountjoy, Joseph McGuirk, Sattva Neelapu, Reem Karmali, Iris Isufi, Brian Hill, Craig Sauter, Catherine Diefenbach, Jay Spiegel, Lizamarie Bachier-Rodriguez, Monalisa Ghosh, Nirav Shah, Rahul Lakhotia, Francisco Hernandez-Ilizaliturri, Anuja Abhyankar, Elise Chong, Matthew Schwede, Krish Patel, Olalekan Oluwole, John Baird, Nathan Denlinger, Farrukh Awan, Michael Jain, John Timmerman, Cesar Sanchez, Muthu Kumaran, Jean Yared, Jon Arnason, Ishan Tatake, Usama Gergis, Peter Riedell, Keith Pratz, Nirali Shah
Journal: Blood
Blood (2025) 146 (Supplement 1): 667.
https://doi.org/10.1182/blood-2025-667
Published: 2025
Journal Articles

Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in Relapsed/Refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial

Free
Zulfa Omer, Alexey Danilov, Francesco Forconi, Talha Munir, Mary Gleeson, Nirav Shah, Graham Collins, Alvaro Alencar, Jane Robertson, Jonathon Cohen, Karan Dixit, Danielle Brander, John Byrd, Allison Winter, Jeffery Smith, Dima El-Sharkawi, Michal Kwiatek, Iwona Hus, Prioty Islam, Sebastian Grosicki, Michael Tees, Thorsten Zenz, Joanna Romejko-Jarosinska, Sarah Injac, Wojciech Jurczak
Journal: Blood
Blood (2025) 146 (Supplement 1): 86.
https://doi.org/10.1182/blood-2025-86
Published: 2025
Journal Articles

Interim analysis of safety and efficacy in a Phase 2 study of MB-105, a CD5.CAR T therapy for patients with relapsed/refractory T cell lymphoma

Free
Swami Iyer, Salvia Jain, Aaron Goodman, Julie Vose, Eric Mou, LaQuisa Hill, Steven Horwitz, Natalie Grover, Anne Beaven, Aleksandr Lazaryan, Malcolm Brenner, Sarah Hein, Federica Giordano, Eric Smith, Robert Michel, Ah-Reum Jeong, Michael Tees, Andy Chen, Shashank Cingam, Maksim Mamonkin, Alice Bexon
Journal: Blood
Blood (2025) 146 (Supplement 1): 775.
https://doi.org/10.1182/blood-2025-775
Published: 2025
Journal Articles

CRC-403: A Phase 1/2 Study of bbT369, a Dual CD79a and CD20 Targeting CAR T Cell Drug Product with a Gene Edit, in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

Free
Frederick L. Locke, David B. Miklos, Michael Tees, Tina Bees, Aojun Li, Anna Truppel-Hartmann, Ian W. Flinn
Journal: Blood
Blood (2022) 140 (Supplement 1): 12716–12717.
https://doi.org/10.1182/blood-2022-162604
Published: 2022
Journal Articles

Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study

Free
Jennifer A. Woyach, Ian W. Flinn, Farrukh T. Awan, Herbert Eradat, Danielle Brander, Michael Tees, Sameer A. Parikh, Tycel J. Phillips, Razi Ghori, Nishitha M. Reddy, Mohammed Z.H. Farooqui, John C. Byrd, Deborah M. Stephens
Journal: Blood
Blood (2022) 140 (Supplement 1): 7004–7006.
https://doi.org/10.1182/blood-2022-163596
Published: 2022
Journal Articles

NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton's Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies

Free
Anthony R. Mato, William G. Wierda, Weiyun Z. Ai, Ian W. Flinn, Michael Tees, Manish R. Patel, Krish Patel, Susan O'Brien, David A. Bond, Lindsey E. Roeker, Tanya Siddiqi, Michael L. Wang, Clare Sun, Omar Abdel-Wahab, Amanda Schwab, May Tan, Erin Meredith, Melissa A. Gessner, Su Young Kim, Adrian Wiestner, Alexey V Danilov
Journal: Blood
Blood (2022) 140 (Supplement 1): 2329–2332.
https://doi.org/10.1182/blood-2022-164772
Published: 2022
Journal Articles

Severe Cytokine Release Syndrome Associated with Worse Outcomes in Recipients of a Haploidentical Stem Cell Transplant

Free
Hayley J Hawkins, Ted A Gooley, Michael Tees
Journal: Blood
Blood (2021) 138 (Supplement 1): 2869.
https://doi.org/10.1182/blood-2021-148514
Published: 2021
Journal Articles

Preliminary Efficacy and Safety of MK-1026, a Non-Covalent Inhibitor of Wild-Type and C481S Mutated Bruton Tyrosine Kinase, in B-Cell Malignancies: A Phase 2 Dose Expansion Study

Free
Jennifer A. Woyach, Ian W. Flinn, Farrukh T. Awan, Herbert Eradat, Danielle M. Brander, Michael Tees, Sameer A. Parikh, Tycel Phillips, Wayne Wang, Nishitha M. Reddy, Mohammed Z.H. Farooqui, John C. Byrd, Deborah M. Stephens
Journal: Blood
Blood (2021) 138 (Supplement 1): 392.
https://doi.org/10.1182/blood-2021-148672
Published: 2021
Journal Articles

ALPHA Study: ALLO-501 Produced Deep and Durable Responses in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Comparable to Autologous CAR T

Free
Sattva S. Neelapu, Rajneesh Nath, Javier Munoz, Michael Tees, David B. Miklos, Matthew J. Frank, Shahbaz A. Malik, Don Stevens, Chu Ri Shin, Arun Balakumaran, Lynn Loomis-Navale, Lovely Goyal, Anh Nguyen, Frederick L. Locke
Journal: Blood
Blood (2021) 138 (Supplement 1): 3878.
https://doi.org/10.1182/blood-2021-146038
Published: 2021
Journal Articles

ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing

Free
Lazaros J. Lekakis, Frederick L. Locke, Michael Tees, Sattva S. Neelapu, Shahbaz A. Malik, Mehdi Hamadani, Matthew J. Frank, Leslie L. Popplewell, Jeremy S. Abramson, Sven de Vos, Javier Munoz, Chu Ri Shin, Arun Balakumaran, Lynn Loomis-Navale, Lovely Goyal, Xiangdong Zhou, David B. Miklos
Journal: Blood
Blood (2021) 138 (Supplement 1): 649.
https://doi.org/10.1182/blood-2021-146045
Published: 2021